Press release: invIOs to present at upcoming conferences
Vienna, Austria, 03 February 2022: invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, today announced the participation at three upcoming investor conferences, the BIO CEO &...
February 3, 2022
No Comments
Press release: APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401
Important development step for promising cell therapy Paradigm shift in cancer treatment: process developed by APEIRON uses immune system to treat solid tumors Innovative new manufacturing and treatment process enables…
July 6, 2021
No Comments
Press release: APEIRON Biologics announces changes to management and supervisory boards
Management Board to be expanded by Romana Gugenberger, PhD, as Chief Medical & Scientific Officer (CMSO) and Andreas Gerber, PhD, as Chief Operating Officer (COO) Prof. Josef Penninger moves from…
June 1, 2021
No Comments
Reactivated immune cells of cancer patients (APN401) for the treatment of solid tumors
In light of the 21st annual #WorldCancerDay we would like to draw your attention to our work in fighting cancer. We at APEIRON Biologics AG want to make a contribution...
February 3, 2021
No Comments
